{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:37:49Z","timestamp":1781624269962,"version":"3.54.5"},"reference-count":20,"publisher":"Korean Cancer Association","issue":"3","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2024,7,15]]},"abstract":"<jats:p>Purpose The aim of this retrospective study was to evaluate the efficacy of adjuvant cisplatin-based chemotherapy in patients with locally advanced upper tract urothelial carcinoma (UTUC), administered following radical nephroureterectomy.Materials and Methods Patients with UTUC, arising from renal pelvis or ureter, staged pT3\/T4 or N+ were treated with adjuvant chemotherapy following surgery. The chemotherapy consisted of gemcitabine 1,000 mg\/m2 on days 1 and 8, cisplatin 70 mg\/m2 on day 1. Treatment was repeated every 3 weeks for up to 4 cycles. Endpoints included disease-free survival (DFS), metastasis-free survival (MFS), and safety.Results Among 89 eligible patients, 85 (95.5%) completed at least 3 cycles of adjuvant chemotherapy. Chemotherapy was well tolerated, the main toxicities being mild-to-moderate gastrointestinal toxic effects and pruritus. With a median follow-up of 37 months, median DFS was 30 months (95% confidence interval, 22 to 39), and the median MFS was not reached. The 3-year DFS and MFS were 44% and 56%, respectively. Multivariate analyses revealed that the main factor associated with DFS and MFS was the lymph node involvement, whereas age, T category, grade, or the primary site of UTUC were not significantly associated with DFS or MFS.Conclusion Adjuvant cisplatin-based chemotherapy after radical surgery of pT3\/T4 or N+ UTUC was feasible and may demonstrate benefits in DFS and MFS. Whether novel agents added to the chemotherapy regimen, as a concurrent combination or maintenance, impacts on survival or reduces the development of metastases remains to be studied.<\/jats:p>","DOI":"10.4143\/crt.2023.1226","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T08:04:11Z","timestamp":1705392251000},"page":"871-876","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study"],"prefix":"10.4143","volume":"56","author":[{"given":"Junho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Hwan","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Chang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24147"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.10.008"},{"key":"ref3","first-page":"1268","volume-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","author":"Birtle","year":"2020"},{"key":"ref4","first-page":"2102","volume-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","author":"Bajorin","year":"2021"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.6_suppl.lba443"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01112-6"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67019-x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.051"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00295-7"},{"key":"ref10","first-page":"202","volume-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","year":"2005"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000273466"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.018"},{"key":"ref13","first-page":"127","volume-title":"Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting","author":"Gupta","year":"2008"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.030"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.3.666"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.011"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.009"},{"key":"ref18","first-page":"2482","volume-title":"Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy","author":"Roscigno","year":"2009"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.004"},{"key":"ref20","first-page":"1218","volume-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","author":"Powles","year":"2020"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2023-1226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2023.1226","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2023-1226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T01:38:07Z","timestamp":1721007487000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2023.1226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2023.1226","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"2023-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-16","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}